These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

545 related items for PubMed ID: 19734225

  • 1. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination.
    Tsuji T, Altorki NK, Ritter G, Old LJ, Gnjatic S.
    J Immunol; 2009 Oct 01; 183(7):4800-8. PubMed ID: 19734225
    [Abstract] [Full Text] [Related]

  • 2. The CD4(+) T-cell response of melanoma patients to a MAGE-A3 peptide vaccine involves potential regulatory T cells.
    François V, Ottaviani S, Renkvist N, Stockis J, Schuler G, Thielemans K, Colau D, Marchand M, Boon T, Lucas S, van der Bruggen P.
    Cancer Res; 2009 May 15; 69(10):4335-45. PubMed ID: 19435913
    [Abstract] [Full Text] [Related]

  • 3. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
    Zhang Y, Renkvist N, Sun Z, Schuler-Thurner B, Glaichenhaus N, Schuler G, Boon T, van der Bruggen P, Colau D.
    Eur J Immunol; 2005 Apr 15; 35(4):1066-75. PubMed ID: 15756643
    [Abstract] [Full Text] [Related]

  • 4. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
    Bonehill A, Heirman C, Tuyaerts S, Michiels A, Zhang Y, van der Bruggen P, Thielemans K.
    Cancer Res; 2003 Sep 01; 63(17):5587-94. PubMed ID: 14500399
    [Abstract] [Full Text] [Related]

  • 5. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
    Bioley G, Dousset C, Yeh A, Dupont B, Bhardwaj N, Mears G, Old LJ, Ayyoub M, Valmori D.
    Clin Cancer Res; 2009 Jul 01; 15(13):4467-74. PubMed ID: 19531622
    [Abstract] [Full Text] [Related]

  • 6. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes.
    Schultz ES, Lethé B, Cambiaso CL, Van Snick J, Chaux P, Corthals J, Heirman C, Thielemans K, Boon T, van der Bruggen P.
    Cancer Res; 2000 Nov 15; 60(22):6272-5. PubMed ID: 11103782
    [Abstract] [Full Text] [Related]

  • 7. The CD4+ T-cell epitope-binding register is a critical parameter when generating functional HLA-DR tetramers with promiscuous peptides.
    Cecconi V, Moro M, Del Mare S, Sidney J, Bachi A, Longhi R, Sette A, Protti MP, Dellabona P, Casorati G.
    Eur J Immunol; 2010 Jun 15; 40(6):1603-16. PubMed ID: 20306469
    [Abstract] [Full Text] [Related]

  • 8. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles.
    Kobayashi H, Song Y, Hoon DS, Appella E, Celis E.
    Cancer Res; 2001 Jun 15; 61(12):4773-8. PubMed ID: 11406551
    [Abstract] [Full Text] [Related]

  • 9. Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients.
    Atanackovic D, Altorki NK, Stockert E, Williamson B, Jungbluth AA, Ritter E, Santiago D, Ferrara CA, Matsuo M, Selvakumar A, Dupont B, Chen YT, Hoffman EW, Ritter G, Old LJ, Gnjatic S.
    J Immunol; 2004 Mar 01; 172(5):3289-96. PubMed ID: 14978137
    [Abstract] [Full Text] [Related]

  • 10. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma.
    Szmania S, Gnjatic S, Tricot G, Stone K, Zhan F, Moreno A, Thuro B, Melenhorst J, Barrett J, Shaughnessy J, Old LJ, Barlogie B, Brichard VG, van Rhee F.
    J Immunother; 2007 Mar 01; 30(8):847-54. PubMed ID: 18049337
    [Abstract] [Full Text] [Related]

  • 11. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
    Dang Y, Knutson KL, Goodell V, dela Rosa C, Salazar LG, Higgins D, Childs J, Disis ML.
    Clin Cancer Res; 2007 Mar 15; 13(6):1883-91. PubMed ID: 17363545
    [Abstract] [Full Text] [Related]

  • 12. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity.
    Dutoit V, Rubio-Godoy V, Dietrich PY, Quiqueres AL, Schnuriger V, Rimoldi D, Liénard D, Speiser D, Guillaume P, Batard P, Cerottini JC, Romero P, Valmori D.
    Cancer Res; 2001 Aug 01; 61(15):5850-6. PubMed ID: 11479225
    [Abstract] [Full Text] [Related]

  • 13. A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients.
    Ayyoub M, Souleimanian NE, Godefroy E, Scotto L, Hesdorffer CS, Old LJ, Valmori D.
    Clin Immunol; 2006 Aug 01; 118(2-3):188-94. PubMed ID: 16368270
    [Abstract] [Full Text] [Related]

  • 14. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming.
    Atanackovic D, Altorki NK, Cao Y, Ritter E, Ferrara CA, Ritter G, Hoffman EW, Bokemeyer C, Old LJ, Gnjatic S.
    Proc Natl Acad Sci U S A; 2008 Feb 05; 105(5):1650-5. PubMed ID: 18216244
    [Abstract] [Full Text] [Related]

  • 15. Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens.
    Baumgaertner P, Rufer N, Devevre E, Derre L, Rimoldi D, Geldhof C, Voelter V, Liénard D, Romero P, Speiser DE.
    Cancer Res; 2006 Feb 15; 66(4):1912-6. PubMed ID: 16488988
    [Abstract] [Full Text] [Related]

  • 16. Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities.
    Connerotte T, Van Pel A, Godelaine D, Tartour E, Schuler-Thurner B, Lucas S, Thielemans K, Schuler G, Coulie PG.
    Cancer Res; 2008 May 15; 68(10):3931-40. PubMed ID: 18483279
    [Abstract] [Full Text] [Related]

  • 17. Endosomal proteases influence the repertoire of MAGE-A3 epitopes recognized in vivo by CD4+ T cells.
    Marturano J, Longhi R, Russo V, Protti MP.
    Cancer Res; 2008 Mar 01; 68(5):1555-62. PubMed ID: 18316621
    [Abstract] [Full Text] [Related]

  • 18. Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein.
    Zhang Y, Sun Z, Nicolay H, Meyer RG, Renkvist N, Stroobant V, Corthals J, Carrasco J, Eggermont AM, Marchand M, Thielemans K, Wölfel T, Boon T, van der Bruggen P.
    J Immunol; 2005 Feb 15; 174(4):2404-11. PubMed ID: 15699177
    [Abstract] [Full Text] [Related]

  • 19. Characterization of mouse MAGE-derived H-2Kb-restricted CTL epitopes.
    Eggert AO, Andersen MH, Voigt H, Schrama D, Kämpgen E, Straten PT, Becker JC.
    Eur J Immunol; 2004 Nov 15; 34(11):3285-90. PubMed ID: 15384049
    [Abstract] [Full Text] [Related]

  • 20. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.
    Jandus C, Bioley G, Dojcinovic D, Derré L, Baitsch L, Wieckowski S, Rufer N, Kwok WW, Tiercy JM, Luescher IF, Speiser DE, Romero P.
    Cancer Res; 2009 Oct 15; 69(20):8085-93. PubMed ID: 19808957
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.